November 25, 2025 4:44pm

Investors watch and wait for any news that can affect the Fed’s rate cut decision?

The C&GT sector bolted upward again while the CBOE Fear (VIX) index closed at 18.56 after Monday’s 20.52 and Friday’s 23.51

RMi collects, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision

It’s not always time to buy or sell; but it is time to KNOW and why!

Never leave an investor uninformed!  

Investors are heading into the shortened Thanksgiving trading week still debating the odds of an interest-rate cut; as San Francisco Fed President Mary Daly said she would support an interest rate cut at the central bank’s December meeting.

RMi Pre-opening Bell: None, waiting in 7 a.m. line (1 of 150) at Outpost Farms, for turkey and its trappings

RMi Research Note: Harvard Apparatus GT (OTCQB): Broke … https://www.regmedinvestors.com/articles/13812

The peril facing the cell and gene therapy (C&GT) sector’s share pricing isn’t just applications of macro or even micro econs, sentiment or algorithms within electronic trading; it’s losing highly reliable, accurate and transparent data.

 

Tuesday: The Dow closed UP +663.93 points or +1.43%, the S&P closed UP +60.77 points or +0.91% while the Nasdaq closed UP +153,586 points or +0.67%

  • Theme of the session: valuating expectations of a Fed interest rate cut

Tuesday’s (my) 40-company covered sector’s advance/decline line opened positive with 30 incliners, 8 decliners and 2 flats ending with a positive close of 24 incliners, 15 decliners and 1 flat

  • Trading volumes are thinning in the coming days

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • According to a Conference Confidence Index for November slumped to 88.7, a drop of 6.8 points from the prior month for its lowest reading since April. Economists surveyed were looking for a reading of 93.2
  • The U.S. labor market is showing further signs of weakening as the pace of layoffs has picked up over the past 4 weeks, private companies lost an average of 13,500 jobs a week over the past four weeks, ADP said as part of a running update it has been providing. That’s an acceleration from the 2,500 jobs a week lost in the last update a week ago.

 

Metrics:  Tuesday …

  • The RUT was up +51.70 points or +2.14%,
  • The XLV was up +3.51 points or +2.26%,
  • The NBI was up +77.68 points or +1.37%;
  • The XBI was up +1.79 points or +1.50%
  • The IWM was up +5.19 or +2.16%;
  • The IBB was up +2.62 points or +1.54%,
  • The VIX was down -1.96 points or -9.55% at to 18.56

 

Q4 – November - 6 positive and 11 negative closes

  • October -1 neutral, 11 positive and 12 negative closes

 

Tuesday Closing UP (10 of 24)

  • Vertex (VRTX +$5.82 after Monday’s -$2.76),
  • Vericel (VCEL +$3.66 after Monday’s -$0.70),
  • IQVIA Holdings (IQV +$3,61 after Monday’s +$3.28),
  • BioNTech (BNTX +$317 after Monday’s +$0.95),
  • Arrowhead Pharma (ARWR +$2.53 after Monday’s +$3.81),
  • Ionis Pharmaceuticals IONS +$2.41),
  • CRISPR Therapeutics (CRSP +$2.32 after Monday’s +$1.02),
  • Regenxbio (RGNX +$1.22),
  • Beam Therapeutics (BEAM +$1.07 after Friday’s +$1.61),
  • Supernus Therapeutics (SUPN +$0.93 after Monday’s -$0.17),

Flat (1)

  • Caribou Biosciences (CRBU)

Tuesday’s Closing DOWN (10 of 15):

  • Alnylam Pharmaceuticals (ALNY -$4.43 after Monday’s -$2.15),
  • Lenz Therapeutics (LENZ -$2.06 after Monday’s -$1.84),
  • Harvard Apparatus RT (OTCQB: HRGN -$0.28 after Monday’s $0.00),
  • Precigen (PGEN -$0.15)
  • Voyager Therapeutics (VYGR -$0.13 after Monday’s -$0.08),
  • Cellectis SA (CLLS -$0.11 after Monday’s +$0.66),
  • Editas Medicine (EDIT -$0.11),
  • Prime Medicine (PRME -$0.07),
  • AxoGen (AXGN +$0.07),
  • Capricor Therapeutics (CAPR -$0.04 after Monday’s -$1.11),

 

The Bottom Line: More of the … WHYs

…  Growing optimism that the Fed will deliver a rate cut next month...

Indexes rose as traders assessed the latest economic data … as Nasdaq soared.

The Russell 2000 is up more than 10% year to date, compared to a 14% rise for the S&P 500 and an 18% jump for the Nasdaq.

Although, shutdown-delayed economic data provided glimpses into consumer spending and price pressures.

  • US retail sales rose in September, though the jump was less than forecast. Meanwhile, a look at wholesale inflation from the same month showed producer prices rising 0.3% month over month, matching expectations but representing a bump from a surprise decline in August.
  • Year-over-year PPI also rose to 2.7%. <Yahoo Finance>

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

A real question, are cell and gene therapy (C&GT) sector companies with high insider ownership present … opportunity?

  • Do they often demonstrate alignment between management and shareholder interests … a critical factor in navigating volatile market conditions?
  • I will be looking into this …! Stay tuned.

 

November: understand the “flow” …

This week:

  • 11/25 – Tuesday closed positive with 24 positive, 15 negative and 1 flat
  • 11/24 - Monday closed positive with 25 positive, 14 negative and 1 flat

Last week:

  • 11/21 - Friday closed positive with 30 positive, 9 negative and 1 flat
  • 11/20 – Thursday closed negative with 8 positive, 31 negative and 1 flat
  • 11/19 – Wednesday closed negative with 10 positive, 27 negative and 3 flats
  • 11/18 – Tuesday closed negative with 18 positive, 21 negative and 1 flat
  • 11/17 – Monday closed negative with 19 positive, 20 negative and 1 flat

 

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:   

  • Tuesday: Vertex (VRTX), Vericel (VCEL) and IQVIA Holdings (IQV)
  • Monday: Arrowhead Pharma (ARWR), IQVIA Holdings (IQV) and Ionis Therapeutics (IONS)
  • Friday: Vertex (VRTX), IQVIA Holdings (IQV) and Ionis Therapeutics (IONS)

The worst three (3) in the session:

  • Tuesday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and Harvard Apparatus RT (OTCQB: HRGN)
  • Monday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Capricor (CAPR)
  • Friday: Alnylam Pharmaceuticals (ALNY), BioNTech (BNTX) and Cellectis SA (CLLS)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.